Looking to win over some skeptical analysts, Rhythm beats the drum on interim data in PhII basket study for additional indications

Rhythm Pharmaceuticals has been working toward expanding the FDA approval they received just two months ago for three rare genetic disorders that result in obesity. In December, their Phase III cut of data saw mixed reactions from analysts, but new interim results released Tuesday may provide more excitement.